GlassScriptPhysician profile
Benjamin G Savage
NPI 1639515281
$22,998.64
in general payments reported to CMS, 2019-2025
29 companies · $5,306 in 2025
The $5,306 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $274 · 2021: $232 · 2022: $5,376 · 2023: $160 · 2024: $11K · 2025: $5,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $718 · Food and Beverage: $707 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,000.00 |
| Travel and Lodging | $717.69 |
| Food and Beverage | $707.13 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15,963.27 | 2019-2025 | Kisunla |
| Argenx US, INC. | $5,177.11 | 2022 | |
| Livanova USA, INC. | $764.69 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $117.47 | 2025 | Ajovy |
| Novartis Pharmaceuticals Corporation | $90.58 | 2019-2022 | |
| Pfizer INC. | $89.48 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $83.01 | 2021 | |
| Allergan, INC. | $65.07 | 2019-2021 | |
| Eisai INC. | $58.26 | 2023-2025 | |
| Emd Serono, INC. | $57.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.36 | 2025 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $42.13 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.61 | 2022 | |
| Tanabe Pharma America, INC. | $39.69 | 2019-2025 | Radicava |
| Sk Life Science, INC. | $38.70 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $38.20 | 2019-2020 | |
| Genentech USA, INC. | $36.75 | 2021-2024 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Ucb, INC. | $27.87 | 2024 | Zilbrysq |
| Janssen Biotech, INC. | $27.69 | 2025 | |
| Merz Pharmaceuticals, LLC | $26.76 | 2021 | |
| Bio Products Laboratory USA, INC. | $23.20 | 2023 | Gammaplex, Coagadex |
| Tg Therapeutics, INC. | $21.26 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.04 | 2023 | Nuedexta |
| Greenwich Biosciences, INC. | $19.64 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.82 | 2025 | |
| Neurelis, INC. | $17.73 | 2022 | |
| Amgen INC. | $16.79 | 2024 | Aimovig |
| Axsome Therapeutics, INC. | $16.60 | 2025 | Symbravo |
| Ge Healthcare | $16.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.